Christoph Wenisch
Overview
Explore the profile of Christoph Wenisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jensen S, Traugott M, Ramazanova D, Haslacher H, Mucher P, Perkmann T, et al.
J Infect Public Health
. 2023 Jul;
16(9):1379-1385.
PMID: 37437431
Background: During the early SARS-CoV-2 pandemic, all healthcare workers had specific and essential functions. However, environmental services (e.g., cleaning staff) and allied health professionals (e.g., physiotherapists) are often less recognised...
12.
Kauer V, Totschnig D, Waldenberger F, Augustin M, Karolyi M, Nageli M, et al.
Viruses
. 2023 May;
15(5).
PMID: 37243267
Objective: The main goal of this study was to assess the potential clinical impact of an outpatient administration of available antivirals including SOT, N/R, and MOL to COVID-19 patients at...
13.
Groza C, Totschnig D, Wenisch C, Atamaniuk J, Zoufaly A
Sci Rep
. 2023 May;
13(1):7896.
PMID: 37193727
The causative agent of the ongoing Corona virus disease 2019 (COVID-19) pandemic, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has acquired a considerable amount of mutations, leading to changes in...
14.
Augustin M, Heyn F, Ullrich S, de Silva U, Albert M, Linne V, et al.
Front Med (Lausanne)
. 2023 May;
10:1129288.
PMID: 37168268
Background: Symptoms lasting longer than 12 weeks after severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection are called post-coronavirus disease (COVID) syndrome (PCS). The identification of new biomarkers that...
15.
Niebauer J, Binder-Rodriguez C, Iscel A, Schedl S, Capelle C, Kahr M, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836071
We aimed to identify cardiopulmonary long-term effects after severe COVID-19 disease as well as predictors of Long-COVID in a prospective registry. A total of 150 consecutive, hospitalized patients (February 2020...
16.
Seitz T, Holbik J, Grieb A, Karolyi M, Hind J, Gibas G, et al.
Viruses
. 2022 Dec;
14(12).
PMID: 36560789
Background: The range of reported rates of bacterial and fungal superinfections in patients with a severe course of COVID-19 is wide, suggesting a lack of standardised reporting. Methods: The rates...
17.
Reindl-Schwaighofer R, Hodlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, et al.
Sci Rep
. 2022 Nov;
12(1):20117.
PMID: 36418458
SARS-CoV-2 gains cell entry via angiotensin-converting enzyme (ACE) 2, a membrane-bound enzyme of the "alternative" (alt) renin-angiotensin system (RAS). ACE2 counteracts angiotensin II by converting it to potentially protective angiotensin...
18.
Karolyi M, Kaltenegger L, Pawelka E, Kuran A, Platzer M, Totschnig D, et al.
Wien Klin Wochenschr
. 2022 Oct;
134(23-24):883-891.
PMID: 36301355
Background: Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality....
19.
Totschnig D, Augustin M, Niculescu I, Laferl H, Jansen-Skoupy S, Lehmann C, et al.
Viruses
. 2022 Oct;
14(10).
PMID: 36298832
Immunocompromised patients experience reduced vaccine effectiveness and are at higher risk for coronavirus disease 19 (COVID-19) death. Pre-exposure prophylaxis (PrEP) aims to protect these patients. So far, only tixagevimab/cilgavimab is...
20.
Fonti M, Mader T, Burmester-Kiang J, Aberle S, Horvath-Mechtler B, Traugott M, et al.
Lancet Rheumatol
. 2022 Oct;
4(11):e804.
PMID: 36247685
No abstract available.